238 related articles for article (PubMed ID: 1546143)
1. Biochemistry and pharmacology of moclobemide, a prototype RIMA.
Haefely W; Burkard WP; Cesura AM; Kettler R; Lorez HP; Martin JR; Richards JG; Scherschlicht R; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S6-14. PubMed ID: 1546143
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE
J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of moclobemide.
Haefely W; Burkard WP; Cesura A; Colzi A; Kettler R; Lorez HP; Martin JR; Moreau JL; Richards JG; Schaffner R
Clin Neuropharmacol; 1993; 16 Suppl 2():S8-18. PubMed ID: 8313402
[TBL] [Abstract][Full Text] [Related]
4. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
Nair NP; Ahmed SK; Kin NM
J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
6. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
[TBL] [Abstract][Full Text] [Related]
7. Some basic aspects of reversible inhibitors of monoamine oxidase-A.
Da Prada M; Kettler R; Burkard WP; Lorez HP; Haefely W
Acta Psychiatr Scand Suppl; 1990; 360():7-12. PubMed ID: 2248079
[TBL] [Abstract][Full Text] [Related]
8. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Gerardy J
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.
Finberg JP
Acta Psychiatr Scand Suppl; 1995; 386():8-13. PubMed ID: 7717096
[TBL] [Abstract][Full Text] [Related]
10. Biochemical aspects of the pharmacology of moclobemide. The implications of animal studies.
Callingham BA
Br J Psychiatry Suppl; 1989 Oct; (6):53-60. PubMed ID: 2619973
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
[TBL] [Abstract][Full Text] [Related]
12. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
Zimmer R
Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
[TBL] [Abstract][Full Text] [Related]
14. Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide.
Cesura AM; Kettler R; Imhof R; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S15-6. PubMed ID: 1546132
[TBL] [Abstract][Full Text] [Related]
15. Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide.
Da Prada M; Kettler R; Keller HH; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():103-5. PubMed ID: 2248059
[TBL] [Abstract][Full Text] [Related]
16. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
Kettler R; Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():101-2. PubMed ID: 2248058
[TBL] [Abstract][Full Text] [Related]
17. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro].
Gol'dina OA; Zagorevskiĭ VA; Lopatina KI; Sokolova TV; Gankina EM
Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical pharmacology of moclobemide. A review of published studies.
Burkard WP; Da Prada M; Keller HH; Kettler R; Haefely W
Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
[TBL] [Abstract][Full Text] [Related]
19. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
[TBL] [Abstract][Full Text] [Related]
20. Brain microdialysis in rats: a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant.
Colzi A; d'Agostini F; Cesura AM; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S17-20. PubMed ID: 1546133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
